



Corporate Announcement

Neugenesis to present at the World Health Organization's Fourth Meeting on Influenza Vaccines that Induce Broad Spectrum and Long-Lasting Immune Responses

Burlingame, California, November 10, 2009

Neugenesis Corporation has been invited to participate in the Fourth Meeting on Influenza Vaccines that Induce Broad Spectrum and Long-Lasting Immune Responses to be held London, England on November 9-10, 2009. The meetings purpose it to review the current status of research in the area of new influenza vaccines, and to define a research agenda for the accelerated development of influenza vaccine with broad-spectrum and/or long-lasting immune responses, as well as novel production and delivery technologies. Debbie Higgins, Director - Vaccine Research and Development will discuss Neugenesis' filamentous fungal production platform as a new technology for the production novel influenza vaccines.

About Neugenesis

Neugenesis Corporation is a privately held biotechnology company which has generated a diverse set of technology platforms for the world wide biotechnology and biopharmaceutical industry. In addition to its new position in vaccines, Neugenesis is also involved in development of technology for production of monoclonal antibodies for biodefense. The Company holds strong intellectual property positions in the areas of production of recombinant monoclonal antibodies, cell based gene-directed evolution, and cell based combinatorial biology. Neugenesis is actively seeking partners in the biopharmaceutical industry to rapidly move the technology into the marketplace.

Contact Information

Laurie Fosner
Neugenesis Corporation
863 Mitten Road, Suite C
Burlingame, CA 94101
(650) 689-2220
www.neugenesis.com.

###